INDEX 267 AUTHOR INDEX Bourbonniere, M., 51 Jenkins, J., 117 Raudonis, B.M., 58 Calarese, P., 152 Kagan, S.H., 1 Reiner, A., 20 Carper, E., 203 Rogers, B.B., 67 Cash, J.C., 242 Lacasse, C., 20 Crighton, M.H., . Levine, A.M., SO Seaman, S., 185 Liebenguth, P.) , 2> 57 Sherwood, P.R., 43 Dest, V.M., 249 Long, J., 97 Steffey-Staey, E.C., 221 Lyder, C.H., 178 Dow, K.H., 129 Steingass, S.K., 65, 107 Duggleby, W., 58 Manson, S.D., 73 Temple, S.V., 257 Gemmill, R., 90 MecNees, P., 129, 130 GiSEvVeOnCE,R , B.B,s , 43‘ McQuestion, M., 163 Toth, P.E., 174 Gosselin-Acomb, T.K., 198 Moore-Higgs, G.J., 233 Van Cleave, J.H., 51 Greco, K., 10 Morse, L., 152 Versea, L,., 97 Haas, M.L., 65, 197, 203 Payne, J.K., 31 Viale, P.H., 144 Hogle, W.P., 212 Puppione, A.A., 3 Visovsky C.,. 36 SUBJECT INDEX Advanced practice nurses, in radiation oncology, 203-211 definition, 221 during brachytherapy, 208 early radiosurgery, 222 in consultation, 207 stereotactic frames, 221-222 during external beam radiation therapy, 208 nurse’s role in, 227-230 during follow-up visits, 208-209 trials and processes in managing after hours care, 209 clinical data, 223-224 in simulation, 207-208 procedural components, 2 2, 244 -W22T7 Bexxar, in radioimmunotherapy for non-Hodgkin's lymphoma, 262-264 Head and neck cancer, effects of radioprotectants on QOL and survivorship in, 251-253 Brachytherapy, 217 tor early stage breast cancer Image-guided CyberKnife radiosurgery, 217 interstitial brachytherapy, 236-237 Image-guided radiotherapy, 216-217 intracavitary brachytherapy, 237-238 Image-guided stereotactic radiosurgery, frameless, 221-232 role of advanced practice nurses during, 208 historical perspectives Breast cancer, early stage, radiation therapy options for, CyberKnife, 222-223 233-241 definition, 221 considerations for nursing care, 240 early radiosurgery, 222 partial breast irradiation, 235-236 stereotactic frames, 221-222 interstitial brachytherapy, 236-237 intracavitary brachytherapy, 5 237-238 nurse’s role in, 227-230 trials and processes intraoperative radiotherapy, > 238 clinical data, 223-224 other techniques, 240 procedural components, 224-227 3-D contormal radiotherapy, 239-240 Infusional toxicities, during radioimmunotherapy for non- surgery and, 234 Hodgkin's lymphoma, 261 whole-breast radiotherapy, 235 Intensity modulated radiation therapy, 216, 242-248 Cancer survivorship, and QOL, effects of radioprotectants advantages of, 242-243 on, 249-255 clinical applications of, 246-247 head and neck cancers, 251-253 implications for nursing practice, 247 history of, 250 planning and delivery, 243-346 lung cancer, 253-254 inverse treatment planning, 244 mechanism of action, 250-251 patient set-up and treatment delivery, 244-246 pelvic cancers, 254 simulation, 244 utilization in clinical practice, Interstitial brachytherapy, for early stage breast cancer, CD20 antigens, in radioimmunotherapy for non-Hodgkin’s 236-237 lymphoma, 258 Intracavitary brachytherapy, for early stage breast cancer, Combined modality therapy, nurse’s role in, 199-200 237-238 safety issues and practice implications, 201 Intraoperative radiation therapy, 217 Consultations, role of advanced practice nurses in, 207 for early stage breast cancer, 238 CyberKnife radiosurgery, image-guided, 217 Inverse treatment planning, in Intensity modulated radiation therapy, 244 External beam radiation therapy, role of advanced practice Irradiation, partial breast, for early stage breast cancer, 235— nurses during, 208 236 interstitial brachytherapy, 236-237 Frameless image-guided stereotactic radiosurgery, intracavitary brachytherapy, 237-238 historical perspectives intraoperative radiotherapy, 238 CyberKnife, 222-223 other techniques, 240 268 INDEX 3-D conformal radiotherapy, 239-240 evolution of, 198-199 Radiation therapy Lung cancer, effects of radioprotectants on QOL and acute effects of, 218 survivorship in, 253-254 cellular response to, 213-214 Lymphoma, non-Hodgkin's. See Non-Hodgkin’s lymphoma external beam, role of advanced practice nurses during, 208 Monoclonal antibodies, in radioimmunotherapy for non- long-term survivorship issues, 218-219 Hodgkin’s lymphoma, 258 options for early stage breast cancer, 233-241 Non-Hodgkin’s lymphoma, radioimmunotherapy for, 257-265 considerations for nursing care, 240 Bexxar regimen, 262-264 partial breast irradiation, 235-240 CD20 antigens, 258 surgery and, 234 monoclonal antibodies, 258 whole-breast radiotherapy, 235 post therapy follow-up, 261-262 treatment modalities, 214-216 pretherapy evaluation, 259-261 brachytherapy, 217 rituximab, 258-259 image-guided CyberKnife radiosurgery, 217 toxicity during infusion, 261 image-guided radiotherapy, 216-217 Zevalin regimen, 264 intensity modulated radiation therapy, 216, 242-248 Nurse’s role, in radiation oncology, 198-202 intraoperative radiation therapy, 217 advanced practice nurses, 203-211 stereotactic radiosurgery, 217 during brachytherapy, 208 Radioimmunotherapy, for non-Hodgkin’s lymphoma, 257- in consultation, 207 265 during external beam radiation therapy, 208 Bexxar regimen, 262-264 during follow-up visits, 208-209 CD20 antigens, 258 in managing after hours care, 209 monoclonal antibodies, 258 in simulation, 207-208 post therapy follow-up, 261-262 in combined modality therapy, 199-200 pretherapy evaluation, 259-261 safety issues and practice implications, 201 rituximab, 258-259 evolution of, 198-199 toxicity during infusion, 261 in trameless image-guided stereotactic radiosurgery, 227 Zevalin regimen, 264 230 Radioprotectants, effects on QOL and survivorship, 249-255 head and neck cancers, 251-253 Oncology, radiation. See Radiation oncology history of, 250 lung cancer, 253-254 Partial breast irradiation, for early stage breast cancer, 235 mechanism of action, 250-251 236 pelvie cancers, 254 interstitial brachytherapy, 236-237 utilization in clinical practice, 251 intracavitary brachytherapy, 237-238 Radiosurgery intraoperative radiotherapy, 238 image-guided CyberKnife, 217 other techniques, 240 stereotactic, 217 3-D conformal radiotherapy, 239-240 frameless image-guided, 221-232 Pelvic cancer, effects of radioprotectants on QOL and Rituximab, in radioimmunotherapy for non-Hodgkin’s survivorship in, 254 lymphoma, 258-259 Quality of life (QOL), and cancer survivorship, effects of Simulation radioprotectants on, 249-255 in intensity modulated radiation therapy, 244 head and neck cancers, 251-253 role of advanced practice nurses in, 207-208 history of, 250 Stereotactic radiosurgery, 217 lung cancer, 253-254 trameless image-guided, 221-232 mechanism of action, 250-251 historical perspectives, 221-223 pelvic cancers, 254 nurse’s role in, 227-230 utilization in clinical practice, 251 trials and processes, 223-227 Surgery, for early stage breast cancer, 234 Radiation oncology, 197 Survivorship. See Cancer survivorship advanced practice nurses, 203-211 during brachytherapy, 208 3-D conformal radiotherapy, for early stage breast cancer, in consultation, 207 239-240 during external beam radiation therapy, 208 Toxicity, infusional, during radioimmunotherapy for non- during follow-up visits, 208-209 Hodgkin’s lymphoma, 261 in managing after hours care, 209 Whole-breast radiotherapy, for early stage breast cancer, 235 in simulation, 207-208 nurse’s role, 198-202 Zevalin, in radioimmunotherapy for non-Hodgkin's in combined modality therapy, 199-201 lymphoma, 264